Pamukkale Unıversity
Denizli, 20000, Turkey (Türkiye)
NCT Number: NCT05872646
Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.
Looking for future studies?
Notify Me30 year–80 year
All sexes
Interventional
Not applicable
Denizli, 20000, Turkey (Türkiye)
Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected.
Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance .
The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
clinical staging
Other names: modifiye hoehn yahr
Time frame: 1 year
Used for clinical staging of Parkinson's disease
Time frame: 1 year
Used for the evaluation of clinical manifestations of Parkinson's disease
Time frame: 1 year
Used to assess the quality of life of Parkinson's patients
Time frame: 1 year
measures the selective attention ability of individuals
Time frame: 1 year
To assess attention, learning, memory and working memory in individuals aged 16-89
Time frame: 1 year
To assess manuel dexterity
Time frame: 1 year
To assess manuel dexterity
Pamukkale University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02795052
ALS, Alzheimer Disease
Westport, Connecticut, United States
View Trial DetailsNCT03234478
Basal Ganglia Diseases, Brain Diseases
New Brunswick, New Jersey, United States
View Trial DetailsNCT06991816
Alzheimer Disease, Anosmia
Naples, Campania, Italy
View Trial DetailsNCT07720713
Basal Ganglia Diseases, Behavior
Dallas, Texas, United States
View Trial Details